29 Apr 2021 11:39
Open Orphan plc
("Open Orphan", the "Company")
Result of General Meeting
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that all resolutions proposed at the General Meeting held earlier today were duly passed.
Further announcements regarding the proposed Distribution in Specie will be made in due course.
For further information, please contact:
Open Orphan plc | www.openorphan.com | ||
Cathal Friel, Executive Chairman | +353 (0) 1 644 0007 | ||
|
| ||
Arden Partners plc (Nominated Adviser and Joint Broker) | +44 (0) 20 7614 5900 | ||
John Llewellyn-Lloyd / Benjamin Cryer / Nick Wright |
| ||
|
| ||
finnCap plc (Joint Broker) | +44 (0) 20 7220 0500 | ||
Geoff Nash / James Thompson/ Richard Chambers |
| ||
|
| ||
Davy (Euronext Growth Adviser and Joint Broker) | +353 (0) 1 679 6363 | ||
Anthony Farrell |
| ||
|
| ||
Walbrook PR (Financial PR & IR) | +44 (0)20 7933 8780 or openorphan@walbrookpr.com | ||
Paul McManus / Sam Allen / Lianne Cawthorne | +44 (0)7980 541 893 / +44 (0)7748 651 727 / +44 (0)7584 391 303 | ||
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic which also has a highly specialised virology and immunology laboratory on-site. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world's first COVID-19 human challenge study model as part of the Human Challenge Programme and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies.
Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion® platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.
Open Orphan's Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company's Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts.